The summarized analysis showed that positive/high ERCC1 expression was associated with unfavorable PFS for SCLC patients receiving platinum-based chemotherapy (HR = 1.46, 95% CI = 1.14–1.88, I2 = 15.1%, P = 0.31 for heterogeneity; Table 2, Figure 5). This evidence concerns the gene ERCC1 and small cell lung carcinoma.